Evidence map›Paper›PMID 40742526›Full record

SynthesisDigestive diseases and sciences2025

Vonoprazan Versus Lansoprazole in the Healing and Maintenance Phase of Erosive Esophagitis: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

Syed Hasham Ali, Sushil Rayamajhi, Hareesha Rishab Bharadwaj, Aditya Gaur, Muhtasim Fuad, Arkadeep Dhali, Dushyant Singh Dahiya, Matan Bone, Babu Mohan, Sushovan Guha

Abstract readComparative StudyNetwork Meta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Syed Hasham Ali *Dow University of Health Sciences, Karachi, Pakistan.
Sushil Rayamajhi *University of Central Florida/HCA Florida West Hospital, Pensacola, FL, USA.
Hareesha Rishab BharadwajFaculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
Aditya GaurYeovil District Hospital, Somerset NHS Foundation Trust, Higher Kingston, Yeovil, UK.
Muhtasim FuadFaculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
Arkadeep DhaliAcademic Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield, UK.
Dushyant Singh DahiyaDivision of Gastroenterology, Hepatology & Motility, The University of Kansas School of Medicine, Kansas City, KS, USA.
Matan BoneSalford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK. matan.bone3@nca.nhs.uk.
Babu MohanUniversity of Central Florida, Orlando, USA.
Sushovan GuhaHouston Regional Gastroenterology Institute (HRGI), Houston, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVonoprazan (VPZ), a potassium-competitive acid blocker, has emerged as an alternative to traditional proton-pump inhibitors like Lansoprazole (LPZ) for the treatment of erosive esophagitis (EE). Vonoprazan provides stronger acid suppression compared to PPIs; however, evidence regarding its effectiveness and safety in treating EE remains limited. We conducted a systematic review and meta-analysis to evaluate the comparative effectiveness and safety of VPZ versus LPZ in the healing and maintenance phases of EE.

methodsA comprehensive literature search was conducted across PubMed, Embase and Cochrane Library to identify eligible randomized controlled trials (RCTs) published till 12 December 2024 that evaluated efficacy and safety of VPZ and LPZ in patients with EE. Outcomes included endoscopic healing rates, recurrence rates, and treatment-emergent adverse events (TEAEs). Pairwise meta-analyses and network meta-analyses (NMA) were performed using Review Manager 5.4.1 and Bayesian models.

resultsThis meta-analysis included 7 RCTs with 4,903 patients. In the healing phase, VPZ showed significantly higher endoscopic healing rates than LPZ at Week 2 (RR: 1.09; 95% CI: 1.04-1.13; p < 0.0001, I

conclusionsVPZ demonstrates greater efficacy in healing and maintaining remission in EE, particularly in severe cases, with a safety profile comparable to LPZ. These findings support VPZ as an effective alternative to PPIs. However, long-term studies are warranted.

Indexed as

EsophagitisEsophagitis, PepticLansoprazoleProton Pump InhibitorsPyrrolesSulfonamidesHumansRandomized Controlled Trials as TopicTreatment Outcome1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineLansoprazoleProton Pump InhibitorsPyrrolesSulfonamidesErosive esophagitis (EE)Healing and maintenance phaseLansoprazoleProton pump inhibitors (PPIs)Vonoprazan

Identifiers

PMID40742526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.